Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Immix Biopharma Inc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
IMMX
Nasdaq
2836
https://immixbio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Immix Biopharma Inc
Immix Biopharma on Track to Dose NXC-201 Patients in United States
- Apr 18th, 2024 1:32 pm
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
- Apr 15th, 2024 1:36 pm
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
- Mar 20th, 2024 1:46 pm
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
- Mar 5th, 2024 2:35 pm
Immix Biopharma 12 Month Review Progress Update
- Feb 21st, 2024 2:31 pm
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
- Feb 8th, 2024 9:45 pm
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
- Feb 7th, 2024 2:37 pm
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
- Feb 6th, 2024 3:30 am
Immix Biopharma Announces Proposed Public Offering of Common Stock
- Feb 5th, 2024 8:20 pm
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
- Jan 24th, 2024 1:35 pm
Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?
- Jan 11th, 2024 11:25 am
Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
- Jan 4th, 2024 2:34 pm
Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
- Dec 18th, 2023 2:39 pm
Insider Spends US$267k Buying More Shares In Immix Biopharma
- Dec 15th, 2023 10:01 am
Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
- Dec 11th, 2023 2:36 pm
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
- Nov 30th, 2023 2:46 pm
What Makes Immix Biopharma, Inc. (IMMX) a Good Fit for 'Trend Investing'
- Nov 28th, 2023 1:50 pm
Pleasing Signs As A Number Of Insiders Buy Immix Biopharma Stock
- Nov 24th, 2023 10:20 am
Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down
- Nov 22nd, 2023 4:10 pm
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
- Nov 22nd, 2023 2:19 pm
Scroll